MedTrace Logo

Study to Investigate Effect of a New Drug (PF-00446687) in Males Suffering From Erectile Dysfunction

NCT00862888 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2009-04-08

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of up to 200 mg of PF-00446687 on erectile activity in males suffering from erectile dysfunction as well as examining the safety and toleration of the drug.

Conditions

Interventions

DRUG

PF-00446687

Single 200mg dose as an oral solution

DRUG

Placebo

Placebo for oral solution

DRUG

Placebo

Placebo for tablet

DRUG

Sildenafil

Single oral dose 100 mg tablet

DRUG

PF-00446687

Single 125 mg dose as an oral solution

DRUG

PF-00446687

Single 175 mg dose as an oral solution

DRUG

PF-00446687

Single 20 mg dose as an oral solution

DRUG

Placebo

Placebo for oral solution

DRUG

Placebo

Placebo for tablet

DRUG

Sildenafil

Single oral dose 100 mg tablet

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Norway
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00862888 on ClinicalTrials.gov